--- title: "China Resources Pharmaceutical Group Seeks to Sell 17.87% Stake in Tianmai Biotechnology" description: "China Resources Pharmaceutical Group Ltd. is looking to sell a 17.87% stake in Hefei Tianmai Biotechnology Development Co., Ltd. through a public tender on the Shanghai United Assets and Equity Exchan" type: "news" locale: "en" url: "https://longbridge.com/en/news/275310826.md" published_at: "2026-02-09T11:44:46.000Z" --- # China Resources Pharmaceutical Group Seeks to Sell 17.87% Stake in Tianmai Biotechnology > China Resources Pharmaceutical Group Ltd. is looking to sell a 17.87% stake in Hefei Tianmai Biotechnology Development Co., Ltd. through a public tender on the Shanghai United Assets and Equity Exchange. The minimum listing price is approximately RMB 1.42 billion. As of now, no buyer has been identified, and the process will end if a suitable transferee is not found. China Resources Pharmaceutical Investment Company Limited, a wholly-owned subsidiary of China Resources Pharmaceutical Group Ltd., has initiated a potential disposal of approximately 17.87% equity interests in Hefei Tianmai Biotechnology Development Co., Ltd. through a public tender process on the Shanghai United Assets and Equity Exchange. The minimum listing price for the stake is set at around RMB 1.42 billion. As of the announcement date, no intended transferee has been identified and no transaction agreements have been signed. The process will lapse if no suitable transferee is found. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12019732), on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [03320.HK - CHINARES PHARMA](https://longbridge.com/en/quote/03320.HK.md) - [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md) - [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md) - [000863.CN - CS精准医](https://longbridge.com/en/quote/000863.CN.md) - [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md) - [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md) - [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md) - [589720.CN - Guotai SSE STAR Brand Name Drug ETF](https://longbridge.com/en/quote/589720.CN.md) - [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md) - [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 埃隆·马斯克的 Neuralink 在中国激发了脑机接口技术的竞赛 | Neuralink，由埃隆·马斯克创立，正在推动中国脑机接口（BCI）发展的热潮，像 NeuroXess 这样的初创公司迅速进入人体试验阶段。NeuroXess 于 2021 年成立，已经在患者身上测试植入物。中国政府已将 BCI 列为战略 | [Link](https://longbridge.com/en/news/276460367.md) | | 华润医药集团有限公司召开了特别股东大会 | 华润医药集团有限公司于 2026 年 2 月 6 日召开了特别股东大会。提议的事项，包括批准 2026/2028 年销售框架协议下的持续关联交易以及对公司章程的修订，均已获得通过 | [Link](https://longbridge.com/en/news/275138791.md) | | 华润三九在华润医药集团的管理下实现了 14.53% 的收入增长 | 华润三九医药股份有限公司（CR Sanjiu），作为华润医药集团有限公司的子公司，报告截至 2025 年 12 月 31 日的财年总营业收入增长 14.53%，达到 316.29 亿元人民币。归属于股东的净利润增长 1.60%，达到 34. | [Link](https://longbridge.com/en/news/275126071.md) | | 昆明制药集团的净利润下降了 24%，因为其附属公司华润医药集团面临行业逆风 | KPC 制药，隶属于华润医药集团，报告称截至 2025 年 12 月 31 日的年度净利润下降了 24%，原因是行业面临挑战。华润通过其子公司华润三九持有 KPC 28.05% 的股份。该财务信息以未经审计的初步数据形式发布。此摘要基于华润 | [Link](https://longbridge.com/en/news/275121318.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.